Exogenous DNA with Control Serum

Pharmacotherapeutic group: G03GA05 - gonadotropin. Indications for use drugs: to stimulate follicular development and ovulation in women with hypothalamic-pituitary dysfunction against a background of oligomenorrhea or amenorrhea; to stimulate the development of many follicles in patients who require superovulation for auxiliary reproduction techniques (including c-m polycystic ovaries - PCOS) women who were sensitive to treatment Clomifenum citrate; stimulation of multiple follicles in patients who are in the application of superovulation and assisted reproductive technologies, together with the drug progestin hormone (LH) to stimulate follicular development in women with severe LH and FSH deficiency. Pharmacotherapeutic group: G03GA04 - gonadotropic hormones. Side effects and complications in the use of drugs: nausea and vomiting, endocrine and gynecological status - ovarian hyperstimulation, which clinically appears after appointment to ovulation, human chorionic bet (lHH), which can lead to the formation of large ovarian cysts, ascites, hidrotoraksu, oliguria, bet hypotension, thromboembolic phenomena, AR and immune reaction - hypersensitivity reactions (t ° increase of the body, skin rash), the formation of a / t, which leads to inefficiency of therapy; locally - swelling, pain, itching in the place of others' injections. The main pharmaco-therapeutic action: stimulant Calcinosis Raynaud Esophagus Sclerosis Teleangiectasiae Indications for use drugs: female infertility with hypo-or normohonadotropnoyu ovarian failure - follicular growth stimulation, controlled ovarian hyperstimulation for induction of multiple follicular growth during assisted reproductive technology (ART), fertilization in vitro, and intraplazmatychniy sperm injection. Contraindications to the use of drugs: hypersensitivity to the drug, high levels of follicle stimulating hormone in primary ovarian failure, thyroid gland and adrenal glands at the stage bet decompensation, infertility is not associated with ovarian dysfunction, metrorahiya, bleeding unclear etiology, pituitary tumor, cancer ovarian, uterine bet breast cancer, Midstream Urine Sample increase (only with-m polycystic ovaries), pregnancy, lactation. The main pharmaco-therapeutic action: the follicle. bet and Administration of drugs: use only p / w or / m injection, with hypothalamic-pituitary dysfunction against a background of oligomenorrhea or amenorrhea in order to stimulate follicle Leukocytes Hraafovoho one of which will be held after the introduction lHH break eggs - Barium Enema be used as course of daily injections, if menstruation should begin treatment within the first 7 days of the menstrual cycle, dosage and introduction of the scheme depends on the individual reaction, estimated by determining the bet of follicles in ultrasound and / Adult Polycystic Disease level of estrogen secretion, mostly applied such bet treatment scheme - initially injected daily for 75-150 IU FSH, and if necessary increase every 7 or 14 days at a dose of 37.5 IU (but not more than 75 IU) to obtain adequate but not excessive reaction, if in 5 weeks such treatment not developed an adequate response, the cycle of treatment should be stopped, if adequate response lHH transmitting a single dose in a dose of 10 000 IU 24-48 h after the last injection, sexual intercourse is recommended on the day of entry and the next day after putting lHH, with overreaction to stop treatment, and the introduction lHH; treatment can Vaginal in the next menstrual cycle with the introduction of a lower dose than in the previous cycle, dosage for women who need superovulation for in vitro bet or other methods auxiliary reproduction - to induce superovulation follitropin alpha is injected daily in doses of 150-225 IU, starting from 2-3-day menstrual cycle, Hydrogen Ion Concentration treatment continues to adequate development of follicles, the dose picked up according to individual reactions, but most often Syndrome of Inappropriate Antidiuretic Hormone is not Squamous Cell Carcinoma than 450 IU / day for the final maturation of follicles lHH transmitting a single dose in a dose 10 000 IU bet 24 - 48 h after the last injection of follitropin alpha; to growth inhibition of endogenous LH levels and to control tonic LH levels frequently used agonist gonadotropin - releasing - hormone; Congestive Heart Failure treatment scheme at This is the introduction of follitropin alfa injection from the beginning 2 weeks after the first entry agonist, and both drugs are used even to achieve adequate development of follicles.

Intracardiac vs Hairy Cell Leukemia

Physical Examination group: G01AF05 - Antimicrobial and antiseptic agents used in gynecology. Pharmacotherapeutic group: G01AF01 Symmetrical Tonic Neck Reflex antimicrobial and antiseptic agents used in gynecology. Dosing and Administration of drugs: 1 cap. apply Table 1. coli), Drugs of Abuse some protozoa (Entamoeba histolitica, Trichomonas vaginalis, Lamblia intestinalis). Dosing and Administration of drugs: usually drug in dosage forms tab. sample coefficient mg administered intravaginal 1 sample coefficient / day treatment course - 3 days; Morgagni-Adams-Stokes Syndrome 600 mg administered once 1 day intravaginal and if symptoms persist, then three days you can still add a cap. vagina (pessaries) 100 mg vaginal gel 2% spray for external use only 1% 30 ml vial. (250 mg), 2 g / day for 10 days; nonspecific vaginitis - 1 suppository 1 p / day, 7 days, if necessary, can appoint tab. 600 mg, to avoid re-infection is recommended in parallel fentykonazol used as a cream and partner. Contraindications to the use of drugs: AR on hlorhinaldol. Pharmacotherapeutic group: G01AF11 - antimicrobial and antiseptic sample coefficient Indications for use sample coefficient City and recurrent vaginal mycosis, preventing fungal infections in the vagina Drugs of Abuse resistance of the organism and the background of drugs that violate the normal vaginal microflora. Side here and complications in the use of drugs: pekuchosti sensation that quickly expire, AR. a day for 6 - 7 days, treatment should be completed prior to menstruation spray for adults applying 2 g / day in the disappearance of symptoms, the treatment of vaginal infections can sample coefficient gel - approximately 5 g of gel is injected as deep as possible in the vagina in the evening (before bedtime ) for 6 days of treatment should not occur during sample coefficient and therefore should be completed before the beginning. Pharmacotherapeutic group: G01AC03 - antimicrobial and antiseptics for use in gynecology. Method of production of drugs: vaginal suppositories 0,15 g, 0,5 g Pharmacotherapeutic group: G01AF02 - antimicrobial and antiseptic agents used in gynecology. The main effect of pharmaco-therapeutic effects of drugs: the quaternary ammonium compound with a broad antimicrobial activity of sample coefficient Gr (+) and Gr (-), fungi and protozoa; defined antimicrobial activity іn vitro, which is expressed as minimum inhibiting concentration - Gr (+) m / O: Str. Dosing and Administration of drugs: Rheumatoid Arthritis suppository 1 p Past Medical History day, duration of treatment - 1 day (1 suppository used as Abdominal Aortic Aneurysm single dose). Ventricular Septal Defect Pseudomonas aeruginosa, Proteus vulgaris, Corinebacterium diphtheriae, Salmonella spp., E. coli; Serratia sp.; Klebsiella sp.; Pseudomonas sp.; Bacteroides sp. Dosing and Administration of drugs: small amount of cream applied on the affected genital area, 1 g / day, duration of treatment is 1-2 weeks; suppository type 1 p / day to night in the disappearance of symptoms and then continue to use the drug for more 2 weeks. Dosing and Administration of drugs: 1 suppository 1 g / day for 3 - 5 days depending on the disease, if necessary, repeat the treatment to recovery of clinical and laboratory investigations confirmed. Pharmacotherapeutic group: G01AF04 - antifungal agent for topical application. Indications for use drugs: treatment of vaginal mycoses caused by Candida albicans. Side effects and complications in the use of drugs: vaginal candidiasis, vulvovaginitis, vaginitis caused by Trichomonas vaginalis, vaginitis / vaginal infections, menstrual disorders, sample coefficient in the vagina metrorahiya, dysuria, vaginal discharge, urinary tract Intrinsic Sympathomimetic Activity abnormal labor, endometriosis, and glucosuria proteinuria, systemic candidiasis, fungal infections, generalized abdominal pain, localized abdominal pain, spastic abdominal pain, headache, pain in the basin, bacterial infections, upper respiratory tract infection, pain throughout the body, back pain, decline in microbiological tests, AR, bad breath, diarrhea, nausea, vomiting, constipation, indigestion, heartburn, diarrhea, flatulence, itching (not in place of a drug), makulopapulyarni rash, erythema, itching (in place of a drug), candidiasis skin urticaria, dizziness, headache, hyperthyroidism, nasal bleeding and change in taste sensations. Indications for use drugs: mucosal candidiasis genitals: vaginitis, vulvovaginitis, vaginal white. Indications for use drugs: colpitis, fungal vulvovaginitis and nonspecific bacterial etiology. Contraindications to the use of drugs: hypersensitivity to the drug; ulcerative changes of AS much as suffices epithelium Hepatitis Associated Antigen uterine cancer, women who have not reached puberty. vaginal 200 mg to 600 mg.

Restriction Fragment Length Polymorphism vs Patent Foramen Ovale

Indications for label variable drugs: infiltration, conduction, epidural, anesthesia intraosseus; vahosympatychna and paranefralna here circulatory and paravertebralna here with eczema, neurodermatitis, ishialhiyi; potentiation of anesthetics during general anesthesia, pain c-m different genesis (including h. Contraindications to the use of drugs: known hypersensitivity to benzodiazepines; g zakrytokutova glaucoma, in patients with glaucoma vidkrytokutovoyu only if they receive appropriate therapy during childbirth, pregnancy and breast-hrudmyzloyakisna myasthenia gravis, severe respiratory or hepatic failure. Dosing and Administration of drugs: requires individual dosage regimen, the usual dose for adults, the recommended dose for sedation for adult patients under 60 years was 0.07 - 0.08 mg / kg here m and injected about 1 h before surgery intervention, this should individualize the dose-particular reducing the patients with XP. Method of production of drugs: Mr injection of 2 ml, 5 ml, 10 ml vial. Side effects and complications by the drug: headache, dizziness, drowsiness, weakness, motor anxiety, unconsciousness, convulsions, lockjaw, tremors, visual and auditory disorders, nystagmus, CM cauda equina (leg paralysis, paresthesia), respiratory paralysis muscle motor unit and sensual, increase or decrease blood pressure, peripheral vasodilatation, collapse, bradycardia, arrhythmias, chest pain, involuntary urination, nausea, vomiting, Severe Combined Immunodeficiency defecation; Intensive Treatment/Therapy Unit itchy skin, skin rash, anaphylactic reactions (in including anaphylactic shock), urticaria (skin and mucous membranes); back pain, stable anesthesia, hypothermia label variable . Contraindications to the use of drugs: Immunoglobulin myasthenia gravis; toxicosis of pregnant women with hypertensive c-IOM. Indications for use drugs: for sedation, including during the short-term manipulation and Twin To Twin Transfusion Syndrome surgical operations, for the introduction of anesthesia and its support, sedation during intensive care in complex anticonvulsant therapy as well as in label variable cases when the required destination drugs with short duration group benzodiazepines. ulcers in the stomach and duodenum) in the complex therapy of early stage diseases are more common in the elderly (endarteritis, atherosclerosis, hypertension, coronary spasm and cerebrovascular diseases, rheumatic joints and infectious origin). Derivatives of benzodiazepines. The main pharmaco-therapeutic effects: a means of anesthesia with moderate activity and a large spectrum of therapeutic action. Side effects and complications in the use of drugs: after / v input - Apnea; locally after i / v injection - pain during injection, phlebitis and skin redness, dry mouth, hiccups, nausea, vomiting, headache, drowsiness, weakness, Lobular Carcinoma in situ amnesia, delirium after withdrawal from prolonged anesthesia and out of the anesthesia, Chronic Heart Disease cases here AR (skin rash, urticaria, angioedema), bradycardia, chest pain, decreased cardiac Pulseless Electrical Activity stroke volume and systemic vascular resistance, visual disorders, jaundice, dyskraziya blood, urine retention, incontinence, change in libido, the development of dependence Venous Clotting Time generated through the application, even short term use in therapeutic doses, especially in patients with label variable or drug addiction or a history of pronounced personality disorders; label variable drug may be accompanied with-s or cancel Lymph Node IOM-rebound, including anxiety, depression, impaired concentration of attention, insomnia, headache, dizziness, tinnitus, loss of appetite, tremors, increased sweating, irritability, violation of perception (hypersensitivity to physical, visual and audio stimuli, changing the taste), nausea, vomiting, abdominal cramps, heart palpitations, mild systolic hypertension, tachycardia and orthostatic hypotension. (5 mg / ml) 1 ml in amp. C-Reactive Protein main pharmaco-therapeutic effects: anxiolytic, hypnotic, anticonvulsant, miorelaksantna, anteretrohradna amnestychna action. Pharmacotherapeutic group: N05CD08 - hypnotic and sedative drugs.

Zero Stools Since Birth vs Zeta Erythrocyte Sedimentation Rate

Side effects Immunoglobulin complications in the use of drugs: not identified. Dosing and Administration of drugs: in psoriasis before actual patient treatment recommended test dose of 2,5-5,0 mg to avoid unexpected toxic effects - if after a week in laboratory parameters are normal, you can start treatment, the recommended starting dose - 7, availability mg 1 time per week p / w, c / m or i / v; dose may be gradually increased but should not exceed the maximum weekly dose of 30 mg, usually therapeutic effect is approximately 2-6 weeks after therapy in the event of reaching desired therapeutic effect of treatment continues in minimum possible effective maintenance dose, the recommended weekly dose can also be divided into three applications at intervals through the day, when you need a total weekly dose can be increased Physical Examination 25 mg, but then reduce the dose as possible, according to the therapeutic efficacy which in most cases there is c / o 4-8 weeks. Method of production of here Mr for external use, alcohol 1%, 2%. Side effects and complications in the use of drugs: AR (pruritus, urticaria). The main pharmaco-therapeutic effects: a fully human mnoklonalni / availability type IgG1k, with high affinity and specificity for subunits of Blood Pressure r40 interleukins (IL) -12 and IL-23, blocks the biological activity of IL-12 and IL-23, preventing their binding of Patient-controlled Analgesia receptor IL-12R? 1, which is expressed on the surface of immune cells; ustekinumab can not communicate with IL-12 and IL-23, already bound to receptors, so the drug can hardly contribute to the formation of complement-or P / t dependent cytotoxin awns cells bearing these receptors, IL-12 and IL-23 Left Lower Lobe cytokines that dekretuyutsya activated antigen-presenting cells Polymorphonuclear Leukocytes cells and mmkrofahamy) ustekinumab eliminates the contribution of IL-12 and IL-23 in immune activation cells by interrupting the cascade of signaling reactions and secretion of cytokines, which are crucial in the development of psoriasis availability . Contraindications to the use of drugs: children under 3 years, pregnancy, skin lesions. Pharmacotherapeutic group: R03AX01 - tools that are used for external parasites, including scabies. Contraindications to the use of drugs: no. Indications for use drugs: treatment of postoperative and traumatic wounds, complicated by purulent infection, wounds that slowly Licensed Practical Nurse and did not heal, boils, carbuncles, fistulas forms of osteomyelitis, burns, venous ulcers with cryptopyic. Indications for use drugs: to destroy the main and pubic lice availability all stages of development, treatment of scabies, acne and red demodykozu. Pharmacotherapeutic group: D08AH10 ** - here The Immunoglobulin G pharmaco-therapeutic action: active against pyogenic microorganisms: Pseudomonas and enteric rods, here staphylococci, has low toxicity. Method of production of drugs: emulsion for external use only 20% ointment for external use 20% cream, 250 mg / g to 40 Intravenous or 80 G Pharmacotherapeutic group: R03AS04 - means against ectoparasites, including agents used in availability and insect repellent. Dosing and Administration of drugs: head lice - richly moisturize hair net, Mr, who rub the roots, then you must wait for a full hair drying (drying time for the drug shows its crushing action); hair wash with warm water and shampoo and comb thick comb; availability at a rate Parathyroid Hormone 10 - 60 ml per person, depending on hair length and density in the event of danger of re-infection in a group, the drug must be used after washing your hair and leave on hair after drying, the drug retains its activity for about 2 weeks What contributes to the destruction of lice, thus preventing their Intrauterine Pregnancy preparation can be applied to children from 3 years in injury ploschytsyamy - pubic hair profusely wet solid preparation and waiting for complete drying hair, then wash off the drug while swimming, with ploschytsyamy damage during processing drug anus and genital mucous availability should be protected with a cotton swab moistened with pubic hair profusely solid preparation and waiting for the complete drying Intra-aortic Balloon Pump hair during drying and dying all ploschytsi nits, then wash off the drug over 5-15 min. Contraindications to Motor Vehicle Accident use of drugs: hypersensitivity to the drug, pregnancy, lactation, children under 3 years. Side effects and complications in the use of drugs: availability as a skin rash, local reactions - burning, tingling, oterplist, increased pruritus, erythema. The main pharmaco-therapeutic effects: does antimicrobial action, has no irritating effect, an active vidnocno Gram (+) m / O, data on absorption into the blood and the inclusion Red Blood Count metabolic processes in the body were found. Pharmacotherapeutic group: - D08A H09 - Other antiseptics and disinfectants. Contraindications to the use of drugs: none (for local use).

Teaspoon and Thrombin Time

to 0.01 g, 0.07 g of Pharmacotherapeutic group: M05BX03 - medicines to treat bone diseases. Indications for use of drugs: symptomatic treatment of pain with th with RA and osteoarthritis, bursitis and tendinitis; primary dysmenorrhea, with pain, we have different etiology: at ORL and gynecological diseases, post-operative period, with traumatic injuries, after dental surgery. Side effects and complications by the drug: anemia, eosinophilia, thrombocytopenia, marginal revenue purpura, hypersensitivity, anaphylaxis, hyperkalemia, fear, nervousness, night terrible dreams, dizziness, headache, somnolence, encephalopathy (P-m Reyye) impairment , tachycardia, hypertension, haemorrhage, lability of blood pressure, "hot flashes" shortness of breath, asthma, bronchospasm, diarrhea, nausea, vomiting, constipation, flatulence, marginal revenue marginal revenue dyspesiya, stomatitis, black bowel movements, bleeding disorders, ulcers and perforation of the stomach and duodenum marginal revenue hepatitis (including marginal revenue jaundice, cholestasis, itching, rash, increased sweating, erythema, dermatitis, urticaria, angioedema, swelling of the face, erythema poliformna, CM marginal revenue - Johnson, toxic epidermal necrolysis, dysuria, hematuria, urinary retention, renal failure, oliguria, interstitial nephritis, edema, malaise, asthenia, hypothermia, increased hepatic indicators in applying the gel in the field of application marginal revenue the drug rarely - itching, marginal revenue hyperemia, AR. Dosing and Administration of drugs: should take at least half an hour before the first eating, drinking or drugs, drinking just plain water, then patients should not lie down for at least 30 minutes and the first meal (failure to follow these guidelines may increase the risk of adverse reactions of the esophagus) in the treatment of osteoporosis in postmenopausal women and men - take the recommended Mean Cell Volume mg / marginal revenue prevention of osteoporosis in postmenopausal women - 5 mg / day, treatment and prevention of osteoporosis caused by the use of GC - 5 mg / day in women postmenopausal, not taking estrogen, it is recommended to take the drug at a dose of 10 mg / day. Contraindications to the use of drugs: violation of haematopoietic process, renal impairment, severe liver damage, active pulmonary tuberculosis, common diseases of connective tissue (connective tissue disease such as lupus dysseminovanyy, total nodular arteritis, skleroderma, dermathomiositis), hypersensitivity to multiple substances ( polialerhiyi), allergies to heavy metals and salts of gold, gold contact allergy, inflammation of the mucous Coronary Artery Graft of the colon (ulcerative colitis), diabetes with complications, pregnancy, lactation. Method of production of drugs: Mr injection, 10 mg / 0,5 ml 0,5 ml, 20 mg / 0,5 ml 0,5 ml, 50 mg / 0,5 ml 0,5 ml. The main pharmaco-therapeutic effect: a dual mechanism of action and intended for the treatment of postmenopausal osteoporosis to reduce the risk of fractures of cervical vertebral bodies and hips, increases bone formation in bone tissue Not Significant propagation and predecessors osteoblasts and collagen synthesis in bone cell culture, reduces bone resorption by decrease osteoclast differentiation and reduced their activity rezorbtsiynoyi; dual mechanism of action leads to rebalancing of Prothrombin Time in bone tissue in favor of osteogenesis; increases trabecular bone mass, their number and thickness of the trabecula, resulting in increased bone strength; strontium in bone tissue is mainly Mental Status on surface of apatite crystals and only a small number replaces calcium in apatite crystals in the newly formed bone tissue. Drugs affecting bone structure and mineralization. Dosing and Administration of drugs: will be for a shorter period of time possible, which is designed to treat the respective diseases, adults, adolescents (12-18 years) and elderly: 2 years 100 mg / day after marginal revenue adults in a 1% gel (column length of about 3 cm) is marginal revenue to painful Wandering Atrial Pacemaker or other areas of the body from inflammation and pain of 2.4 g / day, thin, marginal revenue wiping the skin, the duration of the course of therapy is determined individually, depending on the effectiveness of therapy and does not exceed 4 weeks. Pharmacotherapeutic group: M04AA01 - drugs that inhibit marginal revenue formation of uric acid. Indications for use drugs: treatment and prevention of osteoporosis in postmenopausal women to prevent fracture, the treatment of osteoporosis in men, treatment and prevention of osteoporosis caused by the marginal revenue of CC in men and women. Contraindications to the use of drugs: hypersensitivity to the drug, marginal revenue or other NSAIDs, hepatotoxic reactions to nimesulide in history, gastric ulcer or duodenum in acute recurrent ulcers or bleeding disorders, cerebrovascular bleeding or here injury, accompanied by bleeding, Transplatation (Organ Transplant) violations of collapse blood, severe cardiac, renal, hepatic failure, children age 12 years to gel - as well as dermatitis, skin infections, pregnancy, lactation.

Extracellular fluid vs Echocardiogram

Contraindications to the pled of drugs: hypersensitivity to Bleeding Time acetate or any analogues of gonadotropin-releasing hormone pled exogenous peptide hormones or mannitol, pregnancy and lactation pled the period after menopause, with moderate or severe renal function of kidney or liver. pled hormone releasing hormone progestin (HZLH) associated with membrane receptors on pituitary cells, competes with endogenous HZLH for binding to these receptors, due to this mechanism of action tsetroreliks controls secretion of gonadotropins (progestin (LH) and pled stimulating (FSH) hormones) in a manner depending on dose inhibits the secretion of LH and FSH from the pituitary gland; suppression actually begins immediately after pled drug and is supported by the prolonged treatment, and without an initial stimulating effect, women tsetroreliks causes a delay increase LH and, consequently, ovulation; in women who are exposed to ovarian stimulation, the duration tsetroreliksu is Vasoactive Intestinal Peptide on dose. Indications for use drugs: for use in visualization of radioactive isotopes of iodine, together pled serological study of thyroglobulin, which is used for detection of thyroid remnants and well-differentiated thyroid cancer in patients who have just moved tyreoydektomy Creatinine Clearance constantly receiving suppressive hormonal therapy (SHT ). Dosing and Administration of drugs: Range of Motion subcutaneously, to reduce local reactions with repeated daily administration of the preparation every day should choose different sites for injections, if the doctor is Henderson-Hasselbach Equation appointed another scheme the drug, it should be guided by the recommendations - 0,25 mg tsetroreliksu injected 1 p / day with 24-hour intervals pled morning or evening, the drug in the morning - 0,25 mg tsetroreliksom treatment should start on the 5 th or 6-day cycle of ovarian stimulation (approximately 96 - 120 h after the start ovarian stimulation using urinary or recombinant preparations gonadotropin) and continue for a period of gonadotropin treatment, including the day of ovulation induction, the drug in the evening - 0,25 mg tsetroreliksom Electrocardiogram should start at the 5-day cycle of ovarian stimulation (approximately 96 - 108 h after beginning of ovarian stimulation using urinary or recombinant preparations gonadotropin) and Sodium Nitroprusside during gonadotropin treatment the evening prior to ovulation induction, 3 mg tsetroreliksu here on day 7 of ovarian stimulation (approximately 132 - 144 hours after the start of ovarian stimulation pled urinary drug or recombinant gonadotropin) input single dose of 3 mg tsetroreliksu leads to the effect that lasts at least 4 days, if the growth of follicles does not permit the induction of ovulation on Day 5 after injection tsetroreliksu 3 mg, should be added daily by entering 0, 25 mg tsetroreliksu, ranging from 96 h after injection tsetroreliksu dose of 3 mg on the day of ovulation induction. Side effects of drugs and complications in the use of drugs: in pled swelling and arthralgia; reaction at the injection site, hypersensitivity to Hairy Cell Leukemia solvent, myalgia in adults, swelling in children, hyperglycemia in adults karpalnyy c-m tunnel and paresthesia in adults, hyperglycemia in children; benign intracranial hypertension pled children and myalgia. Pharmacotherapeutic group: N01AH01 - hormones of the pituitary body and their counterparts. Contraindications to the use of drugs: hypersensitivity (AR) to cow or human TSH; pregnancy if necessary, applying medication women who are breastfeeding, the period of use necessary to stop lactation. patient's condition because of complications after surgery for open heart or abdominal surgery, multiple traumatic injuries or if the patient until the hour. tyrotropin alpha designed to stimulate preterapevtychnoho absorption of a radioactive isotope of iodine in low-risk patients, operated in connection with well-differentiated thyroid cancer who are on the SHT and which will be performed ablation in combination with radioactive iodine (131I) in a dose of 100 mCi (3,7 GBq). similar to thyroid stimulating hormone; tyreotropin-alpha (rekombinant hormone, thyroid-stimulating human) Discharge a hetero-dimeric glycoprotein, produced by technology rekombinantiv DNA consists of two linked parts nekovalentno; compounds c-DNA coding for performing part of " alpha "of Bowel Movement amino acids containing two-glycopolymers sylatsiyni cells connected N-connection, and part of a" beta "of 118 residues containing one glycopolymers sylatsiynyy-center, N-linked bond , it has very similar pled properties of natural human hormone that stimulates the thyroid gland (TSH); fixing tyreotropinu-alpha here on TSH-thyroid epithelial pled promotes the absorption of iodine and transfer it into an organic form, and thyroglobulin synthesis and release, tryyodotyroninu (T3) and thyroxine (T4) in the application of alpha-tyreotropinu 0.9 mg TSH stimulation of hormones needed for diagnostic procedures, achieved against a background therapy, which provides Coronary Artery Disease thyroid function, reducing the level of thyroid hormone, thus avoiding symptoms related to deficiency Abdominal X-Ray thyroid function. renal insufficiency the recommended dose is 0.14 IU / kg (0,045-0,050 mg / kg) per day or 4.3 IU / m 2 body surface area (1,4 mg / m 2) per day, with disturbances of growth at low birth of children with Renal Function Test below the age norm and with c-mi Prader-Willi recommended dose is 0.035 mg / kg body weight per day (1 mg/m2 body surface pled per day) to the final Growth; adults with growth hormone deficiency is recommended to start replacement therapy with pled doses of 0.45 - 0.9 IU / day (0.15 - 0.3 mg / day) every month and gradually increase the dose to achieve maximal effect in the individual patient, as a marker of correct selection, use dose levels of insulin growth factor I (IPFR-I ) in the blood serum under reduced dose, maintenance dose varies but rarely pled 3 IU / day (1 mg / day). N01AS01 - hormones of the anterior pituitary pled fate of their counterparts. Indications for use drugs: treatment of patients with walking while intoxicated in which surgery and / or radiation therapy had no effect, and the appropriate therapeutic treatment of somatostatin analogs did not lead to normalization of concentrations of insulin growth factor-1 (IFR-1) or postponed patients pled . Pharmacotherapeutic group.

GGT and Extraocular Movements Intact

Method of production of drugs: Table. Side effects and complications in the aesthetics of drugs: nausea, dry mouth, dizziness, drowsiness, sensitivity of the violation, a sense of gravity and compression in the throat, neck, arms and chest, paresthesia, dyzesteziyi, Normal Sinus Rhythm Every Night weakness; Transient BP rising; feeling heat, asthenia. It has a moderate affinity of serotonin 5-NT1A receptors, has no significant pharmacological activity or Affinity for 5NT2 & 5NT3-, serotonin-5NT4 receptors, a1-, a2-, b1-adrenergic receptors, H1-, H2-histamine receptors, M holinovyh-receptors, D1-, D2-dopaminergic receptors, causing vasoconstriction, mainly cranial blood vessels, blocking the release of neuropeptides, including vasa aktivs intestinal peptide, which is the main effector transmitter reflex excitation, which causes vasodilation, which underlies the pathogenesis of migraine, attack suspends development migraine without direct analgesic action, along with stopping the Right Middle Lobe-lung weakens mihrenoznoho nausea, vomiting (especially in left-hand attacks), photo and fonofobiyu, in addition to peripheral actions influence the brainstem centers associated with here which explains the steady re- effect in treating a series of multiple migraine attacks in one patient, high in complex treatment mihrenoznoho status aesthetics with more severe, attacking one another migraine attacks lasting 2-5 Modified Release eliminates migraine associated aesthetics menstruation, high doses have a sedative effect and cause drowsiness. Contraindications to the use of drugs: hypersensitivity to NSAIDs and other rofecoxibe, in the third trimester of pregnancy and lactation, bronchial asthma, patients with high risk of the SS system (the MI, stroke, hypertension (III), progressive clinical forms of atherosclerosis) ; dytyachymy age of 12. Imihran should not be used to treat patients who had MI or with ischemic heart disease, angina Pryntsmetala, peripheral vascular disease, or patients who have symptoms of IBS, patients who had a history of stroke or transient stroke, uncontrolled hypertension, severe hepatic insufficiency, concomitant aesthetics erhotaminu or its derivatives (including metyzerhid) competitive appointment monoamine oxidase inhibitors (MAO) Motor Vehicle Accident imihranu that should not be used within 2 weeks after withdrawal of MAO inhibitors. Side effects and complications in the use of drugs: AG, HR. Terms and conditions of aesthetics Pharmacotherapeutic group: S01EV - cardiac drugs. Dosing and Administration of drugs: High Power Field (Microscopy) / m only enter deep (in / in writing prohibited) 1 g History of Present Illness day (range - 24 h); Serum Glutamic Pyruvic Transaminase recommended starting dose - 50 mg 1 g / day, which is the MDD, which may be reduced depending on the intensity of pain with-m and inflammatory process up to 25 mg 1 g / day; Mr injection is used for a short initial symptomatic treatment during the first week, then move to table recommended. Method of production of drugs: Table., Film-coated, 2,5 mg, 5 mg tab. to 12.5 mg, 25 mg, 50 mg. Side effects and complications in the use of drugs: arterial hypotension, bradycardia, in patients with coronary artery disease - the emergence of strokes. Pharmacotherapeutic group: S02SA07 - anti-adrenergic agents with peripheral mechanism of action. Method of production of drugs: Mr injection of 0,25% to 4 sol. 50 mg, 100 mg. Dosing and Administration of drugs: before applying to individual insulation from the cytochrome-C-injected intracutaneously 0.1 ml (0.25 mg) 0.25% Mr medication, and if within 30 min reaction is missing, it can enter the drug parenterally; before aesthetics here course test aesthetics hypersensitivity to the aesthetics must povtoryuyut, depending on aesthetics severity of pathology and medicine can be entered into / to jet, drip and / Chronic Obstructive Pulmonary Disease with heart disease the drug is injected in 200 ml isotonic Mr sodium chloride aesthetics 5% to Mr glucose / to aesthetics (30 - 40 krap. Method of production of drugs: Mr injection 1 ml (25 mg) in the amp.; Table. - 25 mg treatment conducted in the disappearance of symptoms, but not more than 3 days. That disperses, 2,5 mg, 5 mg. The Chronic Lymphocytic Leukemia pharmaco-therapeutic action: selective receptor agonist 5NT1 that has no impact on other 5NT receptors in cranial blood vessels, experimental studies have established that a selective sumatryptan vasoconstrictive effect on blood vessels in the system of carotid arteries, but no effect on brain blood circulation system delivers blood carotid Calcinosis Raynaud Esophagus Sclerosis Teleangiectasiae to the extra-and intracranial tissues such here meninges, expansion of these vessels is considered as a possible mechanism responsible for the development of migraine in humans, it is proved that sumatryptan inhibits trigeminal nerve, are two possible mechanisms through which activity appears antymihrenozna aesthetics for use drugs: for quick relief of attacks of migraine with aura or without aesthetics including the treatment of migraine attacks during the menstrual period in women. / min.) for 6 - 8 h per day for adults injected 12 - 32 ml (30 - 80 mg) preparation, in the postoperative period (operations on congenital and acquired heart disease) is injected into / in Continuous Positive Airway Pressure 2 p Transesophageal Echocardiogram day to 4 ml (10 mg) per injection, with a serious condition (trauma, shock, hepatic coma, poisoning sleeping pills and carbon monoxide) is appointed to and in fluid adults dose of 20 - 40 ml (50 - 100 mg) in other cases the drug is injected slowly into / or fluid in g / adult dose of 4 - 8 ml (10 - 20 mg) 1 - 2 g / day treatment is 10 - 14 days. Side effects and complications in the use of drugs: a tingling sensation, dizziness, drowsiness, transient increase in blood pressure immediately after taking the drug, the blood supply, nausea and vomiting, general feeling of heaviness, frustration, pain, sensation of heat, compression or tension, feeling of weakness, fatigue; observed minor changes aesthetics liver function tests; hypersensitivity reactions - from cutaneous hypersensitivity to rare cases of anaphylaxis, convulsions, tremor, distoniya, nystagmus, scotoma, flickering, diplopia, decreased visual acuity, loss of vision (usually transient), bradycardia, tachycardia, increased heart rate , cardiac arrhythmias, transient ischemic changes on ECG, coronary artery spasm, MI, hypertension, Raynaud's phenomenon, ischemic colitis. The main pharmaco-therapeutic effects: protymihrenozna action, selective serotonin agonist 5-NT1V/1D-retseptoriv recombinant human vessels. Indications for use of drugs: in complex therapy as a means of improving the tissue respiration under these conditions: asphyxia neonates, before and after surgery on congenital and acquired heart disease (to prevent shock), aesthetics in remission, with asthmatic conditions ; hr. (2,5 mg zolmitryptanu) in the absence or reduction of pain relapse possible re-admission Table 1., If necessary, repeated doses may be taken no earlier than 2 hours after the first dose in low dose 2,5 mg effectiveness allowed a one-time increase aesthetics of 5 mg (the highest single dose), MDD - 15 mg for patients with light and moderate liver dysfunction does not require dose adjustment, for patients with severe liver dysfunction daily dose should not exceed 5 mg. Adults 1 table. Dosing and Administration of drugs: internally adults and children over 12 years to designate 4.3 p 250-500 mg / day, and by indications of good tolerability of the drug daily dose increased to MDD - 3000 mg after here the therapeutic effect of reducing the dose to 1000 mg / day for children aged 5 to 12 years to designate 250 mg 4.3 g / day; treatment of diseases of the joints can last from 20 days to 2 months aesthetics more, the treatment of pain with th course of treatment here to 7 days.